50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,690.39 (+0.97%)
DOW   29,488.34 (+0.78%)
QQQ   278.11 (+1.36%)
AAPL   153.34 (+1.70%)
MSFT   239.63 (+0.92%)
META   138.37 (+1.47%)
GOOGL   99.06 (+0.91%)
AMZN   115.98 (+0.72%)
TSLA   288.07 (+4.37%)
NVDA   126.59 (+3.52%)
NIO   17.67 (+0.28%)
BABA   79.62 (+0.90%)
AMD   68.20 (+2.87%)
T   16.01 (+2.17%)
MU   50.17 (+2.64%)
CGC   2.91 (+6.20%)
F   12.12 (+1.08%)
GE   65.23 (+1.37%)
DIS   98.96 (+0.86%)
AMC   7.39 (+8.20%)
PYPL   87.24 (+3.54%)
PFE   44.38 (+1.25%)
NFLX   227.91 (+1.71%)
S&P 500   3,690.39 (+0.97%)
DOW   29,488.34 (+0.78%)
QQQ   278.11 (+1.36%)
AAPL   153.34 (+1.70%)
MSFT   239.63 (+0.92%)
META   138.37 (+1.47%)
GOOGL   99.06 (+0.91%)
AMZN   115.98 (+0.72%)
TSLA   288.07 (+4.37%)
NVDA   126.59 (+3.52%)
NIO   17.67 (+0.28%)
BABA   79.62 (+0.90%)
AMD   68.20 (+2.87%)
T   16.01 (+2.17%)
MU   50.17 (+2.64%)
CGC   2.91 (+6.20%)
F   12.12 (+1.08%)
GE   65.23 (+1.37%)
DIS   98.96 (+0.86%)
AMC   7.39 (+8.20%)
PYPL   87.24 (+3.54%)
PFE   44.38 (+1.25%)
NFLX   227.91 (+1.71%)
S&P 500   3,690.39 (+0.97%)
DOW   29,488.34 (+0.78%)
QQQ   278.11 (+1.36%)
AAPL   153.34 (+1.70%)
MSFT   239.63 (+0.92%)
META   138.37 (+1.47%)
GOOGL   99.06 (+0.91%)
AMZN   115.98 (+0.72%)
TSLA   288.07 (+4.37%)
NVDA   126.59 (+3.52%)
NIO   17.67 (+0.28%)
BABA   79.62 (+0.90%)
AMD   68.20 (+2.87%)
T   16.01 (+2.17%)
MU   50.17 (+2.64%)
CGC   2.91 (+6.20%)
F   12.12 (+1.08%)
GE   65.23 (+1.37%)
DIS   98.96 (+0.86%)
AMC   7.39 (+8.20%)
PYPL   87.24 (+3.54%)
PFE   44.38 (+1.25%)
NFLX   227.91 (+1.71%)
S&P 500   3,690.39 (+0.97%)
DOW   29,488.34 (+0.78%)
QQQ   278.11 (+1.36%)
AAPL   153.34 (+1.70%)
MSFT   239.63 (+0.92%)
META   138.37 (+1.47%)
GOOGL   99.06 (+0.91%)
AMZN   115.98 (+0.72%)
TSLA   288.07 (+4.37%)
NVDA   126.59 (+3.52%)
NIO   17.67 (+0.28%)
BABA   79.62 (+0.90%)
AMD   68.20 (+2.87%)
T   16.01 (+2.17%)
MU   50.17 (+2.64%)
CGC   2.91 (+6.20%)
F   12.12 (+1.08%)
GE   65.23 (+1.37%)
DIS   98.96 (+0.86%)
AMC   7.39 (+8.20%)
PYPL   87.24 (+3.54%)
PFE   44.38 (+1.25%)
NFLX   227.91 (+1.71%)

Compare Stocks

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$144.71
+2.5%
$141.61
$106.86
$175.91
$255.86B0.725.11 million shs159,769 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$166.74
+0.6%
$167.66
$155.72
$186.69
$438.39B0.617.36 million shs96,002 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$312.67
+1.7%
$313.64
$220.20
$335.33
$297.09B0.382.57 million shs33,814 shs
Pfizer Inc. stock logo
PFE
Pfizer
$44.38
+1.3%
$48.11
$40.94
$61.71
$249.08B0.716.98 million shs310,468 shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-1.29%-1.02%+3.56%-7.40%+31.89%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.61%-0.35%+0.87%-6.35%+0.82%
Eli Lilly and Company stock logo
LLY
Eli Lilly and
-1.27%+0.79%-2.55%-3.19%+32.73%
Pfizer Inc. stock logo
PFE
Pfizer
-0.57%-3.54%-6.39%-13.48%-0.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
2.60 of 5 Stars
2.35.04.23.92.01.71.3
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.32 of 5 Stars
2.33.04.23.91.21.71.3
Eli Lilly and Company stock logo
LLY
Eli Lilly and
2.61 of 5 Stars
1.43.03.34.01.93.33.1
Pfizer Inc. stock logo
PFE
Pfizer
3.25 of 5 Stars
3.35.05.04.31.81.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.50
Moderate Buy$159.3512.85% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.56
Moderate Buy$189.7814.53% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and
2.81
Moderate Buy$332.198.03% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.50
Moderate Buy$57.0030.05% Upside

Current Analyst Ratings

Latest JNJ, LLY, ABBV, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2022
Eli Lilly and Company stock logo
LLY
Eli Lilly and
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$335.00 ➝ $363.00
9/14/2022
Pfizer Inc. stock logo
PFE
Pfizer
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$44.00
9/12/2022
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight$174.00 ➝ $173.00
9/7/2022
Eli Lilly and Company stock logo
LLY
Eli Lilly and
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight$395.00 ➝ $412.00
9/6/2022
Eli Lilly and Company stock logo
LLY
Eli Lilly and
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform$369.00 ➝ $396.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$59.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$59.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
(Data available from 9/27/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.20B4.44$17.43 per share8.10$8.73 per share16.18
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$93.78B4.65$12.68 per share13.07$28.12 per share5.89
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$28.32B10.32$9.27 per share33.16$9.57 per share32.13
Pfizer Inc. stock logo
PFE
Pfizer
$81.29B3.03$5.39 per share8.13$13.80 per share3.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$11.54B$7.0620.0011.974.0222.03%158.41%16.34%11/4/2022 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$20.88B$6.8724.1215.772.9819.21%36.14%14.88%10/18/2022 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$5.58B$6.2749.0432.682.0219.58%85.58%15.79%10/25/2022 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$21.98B$5.118.588.160.5428.92%43.18%18.89%11/1/2022 (Confirmed)

Latest JNJ, LLY, ABBV, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/1/2022N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.66N/A-$1.66N/AN/AN/A  
10/18/2022N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.57N/A-$2.57N/AN/AN/A  
8/4/2022Q2
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$1.86$1.25-$0.61N/A$6.85 billion$6.49 billion      
7/29/2022Q2 2022
AbbVie Inc. stock logo
ABBV
AbbVie
$3.42$3.51+$0.09$6.51$14.64 billion$14.58 billion    
7/28/2022Q2
Pfizer Inc. stock logo
PFE
Pfizer
$1.95$2.04+$0.09N/A$26.20 billion$27.74 billion    
7/19/2022Q2 2022
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.57$2.59+$0.02$3.38$23.85 billion$24.02 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$5.643.99%+10.37%79.89%50 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.522.73%+5.78%65.79%60 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and
$3.921.27%+14.81%62.52%8 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.603.65%+4.39%31.31%11 Years

Latest JNJ, LLY, ABBV, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/22/2022
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.403.64%11/3/202211/4/202212/5/2022
9/9/2022
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.413.98%10/13/202210/14/202211/15/2022
6/27/2022
Eli Lilly and Company stock logo
LLY
Eli Lilly and
quarterly$0.981.2%8/12/20228/15/20229/9/2022
7/18/2022
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Quarterly$1.132.63%8/22/20228/23/20229/6/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
4.15
0.84
0.75
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.37
1.42
1.17
Eli Lilly and Company stock logo
LLY
Eli Lilly and
1.70
1.10
0.85
Pfizer Inc. stock logo
PFE
Pfizer
0.39
1.42
1.20

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
68.25%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
68.59%
Eli Lilly and Company stock logo
LLY
Eli Lilly and
82.45%
Pfizer Inc. stock logo
PFE
Pfizer
67.9%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.35%
Eli Lilly and Company stock logo
LLY
Eli Lilly and
0.12%
Pfizer Inc. stock logo
PFE
Pfizer
0.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
141,7002.63 billion2.62 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and
35,000950.17 million949.04 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
79,0005.61 billion5.61 billionOptionable

JNJ, LLY, PFE, and ABBV Headlines

SourceHeadline
UQ startup acquired by Pfizer - UQ News - University of QueenslandUQ startup acquired by Pfizer - UQ News - University of Queensland
uq.edu.au - September 26 at 11:51 PM
Pfizer vs. Moderna: What are the new bivalent boosters’ differences? - WJW FOX 8 News ClevelandPfizer vs. Moderna: What are the new bivalent boosters’ differences? - WJW FOX 8 News Cleveland
fox8.com - September 26 at 11:51 PM
Pfizer launches patient support app to improve access to medication - Gulf BusinessPfizer launches patient support app to improve access to medication - Gulf Business
gulfbusiness.com - September 26 at 11:51 PM
Mass Hospital Layoffs; Pfizer CEO Has COVID Again; Blood on Your Hands - Medpage TodayMass Hospital Layoffs; Pfizer CEO Has COVID Again; 'Blood on Your Hands' - Medpage Today
medpagetoday.com - September 26 at 11:51 PM
Pfizer executive: Drugmakers should rethink supply chain logistics - Beckers Hospital ReviewPfizer executive: Drugmakers should 'rethink' supply chain logistics - Becker's Hospital Review
beckershospitalreview.com - September 26 at 11:51 PM
Fitch Revises Pfizers Outlook to Positive; Affirms IDR at A - Fitch RatingsFitch Revises Pfizer's Outlook to Positive; Affirms IDR at 'A' - Fitch Ratings
fitchratings.com - September 26 at 11:51 PM
Pfizer strengthens AI drug discovery collaboration with equity investment - OutSourcing-Pharma.comPfizer strengthens AI drug discovery collaboration with equity investment - OutSourcing-Pharma.com
outsourcing-pharma.com - September 26 at 11:51 PM
Pfizer (PFE) Stock Moves -0.57%: What You Should KnowPfizer (PFE) Stock Moves -0.57%: What You Should Know
finance.yahoo.com - September 26 at 11:51 PM
Pfizer seeks FDA nod for Omicron-retooled booster for kids aged 5-11 yrsPfizer seeks FDA nod for Omicron-retooled booster for kids aged 5-11 yrs
nasdaq.com - September 26 at 1:50 PM
Pfizer/BioNTech seek FDA nod for new COVID boosters for childrenPfizer/BioNTech seek FDA nod for new COVID boosters for children
reuters.com - September 26 at 1:50 PM
Pfizer, BioNTech Apply For EUA In US Of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster In KidsPfizer, BioNTech Apply For EUA In US Of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster In Kids
nasdaq.com - September 26 at 1:50 PM
Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11
msn.com - September 26 at 1:50 PM
RAW: COVID: PFIZER, BIOTECH SEEK EMERG USE FOR KIDS BOOSTER - 69News WFMZ-TVRAW: COVID: PFIZER, BIOTECH SEEK EMERG USE FOR KIDS BOOSTER - 69News WFMZ-TV
wfmz.com - September 26 at 8:49 AM
Pfizer/BioNTech seek FDA nod for new COVID boosters for children - KFGOPfizer/BioNTech seek FDA nod for new COVID boosters for children - KFGO
kfgo.com - September 26 at 8:49 AM
Pfizer vs. Moderna: What are the new bivalent boosters’ differences? - KFOR Oklahoma CityPfizer vs. Moderna: What are the new bivalent boosters’ differences? - KFOR Oklahoma City
kfor.com - September 26 at 8:49 AM
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age - PfizerPfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age - Pfizer
pfizer.com - September 26 at 8:49 AM
New pediatric Pfizer vaccine, COVID-19 bivalent booster available starting Monday - CBC.caNew pediatric Pfizer vaccine, COVID-19 bivalent booster available starting Monday - CBC.ca
cbc.ca - September 25 at 8:39 PM
Pfizer vs. Moderna: What are the new bivalent boosters differences? - The HillPfizer vs. Moderna: What are the new bivalent boosters' differences? - The Hill
thehill.com - September 25 at 9:31 AM
Little Excitement Around Pfizer Inc.s (NYSE:PFE) EarningsLittle Excitement Around Pfizer Inc.'s (NYSE:PFE) Earnings
finance.yahoo.com - September 25 at 9:31 AM
Pfizer CEO tests positive for COVID-19 again - The HillPfizer CEO tests positive for COVID-19 again - The Hill
thehill.com - September 24 at 8:08 PM
Pfizer CEO tests positive for COVID for a second time - ReutersPfizer CEO tests positive for COVID for a second time - Reuters
reuters.com - September 24 at 8:08 PM
Pfizer CEO tests positive for COVID-19 for a second timePfizer CEO tests positive for COVID-19 for a second time
ctvnews.ca - September 24 at 7:50 PM
Covid-19 Vaccine Rollout Carries Lessons for Pharma Supply Chains, Says Pfizer Executive - The Wall Street JournalCovid-19 Vaccine Rollout Carries Lessons for Pharma Supply Chains, Says Pfizer Executive - The Wall Street Journal
wsj.com - September 24 at 10:07 AM
Pfizer To Supply 6 Mln Paxlovid Treatment Courses To Fight Covid-19Pfizer To Supply 6 Mln Paxlovid Treatment Courses To Fight Covid-19
markets.businessinsider.com - September 24 at 12:06 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Eli Lilly and logo

Eli Lilly and

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.